	US 11,806,342 B2
	Diiodohydroxyquinoline for the treatment of clostridium difficile infection
Mohamed Seleem, West Lafayette, IN (US); and Nader Abutaleb, West Lafayette, IN (US)
Assigned to Purdue Research Foundation, West Lafayette, IN (US)
Filed by Purdue Research Foundation, West Lafayette, IN (US)
Filed on Oct. 6, 2020, as Appl. No. 17/063,750.
Claims priority of provisional application 62/911,594, filed on Oct. 7, 2019.
Prior Publication US 2021/0100787 A1, Apr. 8, 2021
Int. Cl. A61K 38/14 (2006.01); A61K 9/00 (2006.01); A61K 31/47 (2006.01); A61K 31/7048 (2006.01); A61K 31/4164 (2006.01)

CPC A61K 31/47 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0053 (2013.01); A61K 31/4164 (2013.01); A61K 31/7048 (2013.01); A61K 38/14 (2013.01)]

6 Claims

1. A method of treating a patient previously infected by Clostridium difficile comprising administering a therapeutically effective spore-inhibiting amount of 5,7-diiodoquinolin-8-ol, together with one or more agents, wherein the agent is vancomycin or fidaxomicin, and one or more pharmaceutically acceptable carriers, diluents, and excipients, to the patient in need of relief from recurrence of said infection.